Literature DB >> 23942221

Differential receipt of sentinel lymph node biopsy within practice-based research networks.

Anne-Marie Meyer1, Katherine E Reeder-Hayes, Huan Liu, Stephanie B Wheeler, Dolly Penn, Bryan J Weiner, William R Carpenter.   

Abstract

BACKGROUND: Practice-based research networks (PBRNs) are promising for accelerating not only research, but also dissemination of research-based evidence into broader community practice. Sentinel lymph node biopsy (SLNB) is an innovation in breast cancer care associated with equivalent survival and lower morbidity, as compared with standard axillary lymph node dissection. We examined the diffusion of SLNB into practice and whether affiliation with the Community Clinical Oncology Program (CCOP), a cancer-focused PBRN, was associated with more rapid uptake of SLNB. RESEARCH
DESIGN: Surveillance Epidemiology and End Results-Medicare data were used to study women diagnosed with stage I or II breast cancer in the years 2000-2005 and undergoing breast-conserving surgery with axillary staging (n=6226). The primary outcome was undergoing SLNB. CCOP affiliation of the surgical physician was ascertained from NCI records. Multivariable generalized linear modeling with generalized estimating equations was used to measure association between CCOP exposure and undergoing SLNB, controlling for potential confounders.
RESULTS: Women treated by a CCOP physician had significantly higher odds of receiving SLNB compared with women treated by a non-CCOP physician (OR 2.68; 95% CI, 1.35-5.34). The magnitude of this association was larger than that observed among patients treated by physicians operating in medical school-affiliated hospitals (OR 1.76; 95% CI, 1.30-2.39).
CONCLUSIONS: Women treated by CCOP-affiliated physicians were more likely to undergo SLNB irrespective of the hospital's medical school affiliation, suggesting that the CCOP PBRN may play a role in the rapid adoption of research-based innovation in community practice.

Entities:  

Mesh:

Year:  2013        PMID: 23942221      PMCID: PMC4080805          DOI: 10.1097/MLR.0b013e31829c8ca4

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  25 in total

1.  Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.

Authors:  Joan L Warren; Carrie N Klabunde; Deborah Schrag; Peter B Bach; Gerald F Riley
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

2.  Practice-based research--"Blue Highways" on the NIH roadmap.

Authors:  John M Westfall; James Mold; Lyle Fagnan
Journal:  JAMA       Date:  2007-01-24       Impact factor: 56.272

3.  The role of organizational affiliations and research networks in the diffusion of breast cancer treatment innovation.

Authors:  William R Carpenter; Katherine Reeder-Hayes; John Bainbridge; Anne-Marie Meyer; Keith D Amos; Bryan J Weiner; Paul A Godley
Journal:  Med Care       Date:  2011-02       Impact factor: 2.983

4.  Race and age disparities in receipt of sentinel lymph node biopsy for early-stage breast cancer.

Authors:  Katherine E Reeder-Hayes; John Bainbridge; Anne Marie Meyer; Keith D Amos; Bryan J Weiner; Paul A Godley; William R Carpenter
Journal:  Breast Cancer Res Treat       Date:  2011-02-22       Impact factor: 4.872

Review 5.  Variations in breast cancer treatment by patient and provider characteristics.

Authors:  J Z Ayanian; E Guadagnoli
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

6.  A framework for understanding cancer comparative effectiveness research data needs.

Authors:  William R Carpenter; Anne-Marie Meyer; Amy P Abernethy; Til Stürmer; Michael R Kosorok
Journal:  J Clin Epidemiol       Date:  2012-11       Impact factor: 6.437

7.  Disentangling the effects of race on breast cancer treatment.

Authors:  Mousumi Banerjee; Julie George; Cecilia Yee; William Hryniuk; Kendra Schwartz
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

8.  Racial differences in definitive breast cancer therapy in older women: are they explained by the hospitals where patients undergo surgery?

Authors:  Nancy L Keating; Elena Kouri; Yulei He; Jane C Weeks; Eric P Winer
Journal:  Med Care       Date:  2009-07       Impact factor: 2.983

9.  A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients.

Authors:  Carrie N Klabunde; Julie M Legler; Joan L Warren; Laura-Mae Baldwin; Deborah Schrag
Journal:  Ann Epidemiol       Date:  2007-05-25       Impact factor: 3.797

10.  Predictors of timing of adjuvant chemotherapy in older women with hormone receptor-negative, stages II-III breast cancer.

Authors:  Stephanie B Wheeler; William R Carpenter; Jeffrey Peppercorn; Anna P Schenck; Morris Weinberger; Andrea K Biddle
Journal:  Breast Cancer Res Treat       Date:  2011-08-13       Impact factor: 4.872

View more
  8 in total

1.  Prevalence and Consequences of Axillary Lymph Node Dissection in the Era of Sentinel Lymph Node Biopsy for Breast Cancer.

Authors:  Tina W F Yen; Purushottam W Laud; Liliana E Pezzin; Emily L McGinley; Erica Wozniak; Rodney Sparapani; Ann B Nattinger
Journal:  Med Care       Date:  2018-01       Impact factor: 2.983

2.  Provider-based research networks and diffusion of surgical technologies among patients with early-stage kidney cancer.

Authors:  Hung-Jui Tan; Anne-Marie Meyer; Tzy-Mey Kuo; Angela B Smith; Stephanie B Wheeler; William R Carpenter; Matthew E Nielsen
Journal:  Cancer       Date:  2014-11-19       Impact factor: 6.860

3.  Breast Cancer Disparities at Home and Abroad: A Review of the Challenges and Opportunities for System-Level Change.

Authors:  Katherine E Reeder-Hayes; Benjamin O Anderson
Journal:  Clin Cancer Res       Date:  2017-06-01       Impact factor: 12.531

4.  Enrollment and Racial Disparities in Cancer Treatment Clinical Trials in North Carolina.

Authors:  Leah L Zullig; Alice G Fortune-Britt; Shangbang Rao; Seth D Tyree; Paul A Godley; William R Carpenter
Journal:  N C Med J       Date:  2016 Jan-Feb

5.  Racial Differences in Diffusion of Intensity-Modulated Radiation Therapy for Localized Prostate Cancer.

Authors:  Ewan K Cobran; Ronald C Chen; Robert Overman; Anne-Marie Meyer; Tzy-Mey Kuo; Jonathon O'Brien; Til Sturmer; Nathan C Sheets; Gregg H Goldin; Dolly C Penn; Paul A Godley; William R Carpenter
Journal:  Am J Mens Health       Date:  2015-02-05

6.  Associations Between Sentinel Lymph Node Biopsy and Complications for Patients with Ductal Carcinoma In Situ.

Authors:  Brigid K Killelea; Jessica B Long; Weixiong Dang; Sarah S Mougalian; Suzanne B Evans; Cary P Gross; Shi-Yi Wang
Journal:  Ann Surg Oncol       Date:  2018-03-07       Impact factor: 5.344

7.  The interplay between hospital and surgeon factors and the use of sentinel lymph node biopsy for breast cancer.

Authors:  Tina W F Yen; Jianing Li; Rodney A Sparapani; Purushuttom W Laud; Ann B Nattinger
Journal:  Medicine (Baltimore)       Date:  2016-08       Impact factor: 1.889

8.  Long-Term Outcomes of Sentinel Lymph Node Biopsy for Ductal Carcinoma in Situ.

Authors:  Peiyin Hung; Shi-Yi Wang; Brigid K Killelea; Sarah S Mougalian; Suzanne B Evans; Tannaz Sedghi; Cary P Gross
Journal:  JNCI Cancer Spectr       Date:  2019-08-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.